Insights
08 Oct
CAR-T Moves Beyond Oncology
CAR-T Moves Beyond Oncology: Could Immune Reset Become the Next Frontier? By Eminent Global Research Solutions Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for several blood cancers. But the next chapter of CAR-T may not be defined by oncology alone. Researchers are increasingly investigating whether the same cellular-engineering principles used […]
07 Oct
AI Drug Discovery Faces the Challenge of Translating Data Into Clinical Success
Artificial intelligence is rapidly changing how pharmaceutical companies identify targets, design molecules, predict properties, and prioritize drug candidates. From protein-structure prediction and virtual screening to de novo molecular design and multimodal analysis, AI can compress parts of the discovery process that traditionally required years of experimentation. But a critical question is becoming increasingly important: Can […]
05 Oct
Pharma M&A Accelerates as Patent Cliff Pressure Builds
How loss-of-exclusivity exposure is reshaping pharmaceutical portfolio strategy, dealmaking, and competitive positioning The pharmaceutical M&A landscape is entering a strategically important phase. Large drugmakers are facing increasing pressure to replace revenue that could be eroded as blockbuster medicines approach loss of exclusivity (LOE), while at the same time seeking exposure to new growth markets, differentiated […]
01 Oct
FDA Advances Electronic Submissions for Medical Device PMAs
The U.S. Food and Drug Administration (FDA) is taking another significant step toward modernizing the way medical device companies prepare and submit Premarket Approval Applications (PMAs). In September 2026, FDA issued a draft guidance on the Electronic Submission Template for Premarket Approval Applications (PMA). The guidance introduces the current electronic resources available for PMA and […]
29 Sep
AI Enters Cosmetic Safety and Adverse-Event Monitoring
AI Enters Cosmetic Safety and Adverse-Event Monitoring: From Reactive Reporting to Predictive Cosmetovigilance The cosmetics industry is entering a new phase of safety management. As product portfolios become more complex, consumer expectations rise, and regulatory oversight expands, cosmetic companies are facing a growing need to identify, classify, investigate, and respond to adverse events more efficiently. […]
28 Sep
Cell & Gene Therapy 2030: From Scientific Innovation to Commercial Scale
Cell and gene therapy (CGT) has moved from being primarily an experimental frontier to an increasingly established therapeutic modality. The scientific question is no longer simply whether cells or genetic material can be engineered to treat disease. The larger strategic question is whether these therapies can be manufactured consistently, regulated efficiently, delivered to patients, and […]
25 Sep
FDA Updates Regulations to Advance Alternatives to Animal Testing
Industry: Pharmaceuticals | Biotechnology | Regulatory Intelligence | Drug Development The U.S. Food and Drug Administration (FDA) has taken another significant step toward modernizing nonclinical drug development by updating its regulations to formally recognize a broader range of testing approaches beyond traditional animal studies. On September 21, 2026, the FDA issued a direct final rule […]
24 Sep
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
A New Milestone for Rare Disease Treatment The U.S. Food and Drug Administration (FDA) has approved FAYUVI (rebisufligene etisparvovec-hopf), developed by Ultragenyx Pharmaceutical, for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A. The September 17, 2026 approval represents the first FDA-approved treatment for MPS IIIA and introduces a […]
23 Sep
What the 2026 FDA Expedited IND Pilot Means for Pharma Strategy
The pharmaceutical industry is entering a period in which regulatory strategy may increasingly influence not only compliance but also the speed and economics of innovation. The U.S. FDA’s 2026 Expedited Investigational New Drug (IND) Pilot Program is an important example of this shift. Launched on September 15, 2026 under HHS’s Operation TrialBlazer, the pilot is […]
22 Sep
Is Platform Technology Becoming More Valuable Than Individual Biotechnology Products?
Biotechnology has traditionally been evaluated through the lens of individual products: a novel therapy, a breakthrough diagnostic, a proprietary enzyme, or a differentiated biological ingredient. However, the economics of the biotechnology industry are increasingly creating a different strategic question: Is the platform behind the product becoming more valuable than the product itself? A successful biotechnology […]